Skip to content
This GLP
← Research
Safety

Hair loss: five studies, and they disagree

A systematic review found five primary studies in 2,905 adults. Some reported hair loss, some reported regrowth, and the review's own conclusion is that the findings conflict.

Ruth Alvarez4 min read
What five studies foundhair loss reportedregrowth reported2,905 adults across five studies, mostly weekly tirzepatide.The review’s own conclusion: findings conflict.

Hair loss is one of the most searched questions about these drugs and one of the least answered. A 2025 systematic review searched three databases for every primary study in English on the subject, found five, and pooled 2,905 adults — most of them taking weekly tirzepatide [1]. Its conclusion is that the studies disagree. That is a real result and it is not the one anybody wants, so it is worth reading before a seller’s product page answers it for you.

What the five studies showed

Some reported hair loss as an adverse dermatological event. Others reported significant improvement and hair regrowth. The review describes the findings as conflicting and recommends further research to clarify the relationship — which is the standard phrasing for a question the literature cannot currently settle.

The starting point was the FDA’s adverse event reporting system, which had flagged several dermatological effects including hair loss. A reporting signal is a reason to look, not a finding in itself, and looking has so far produced disagreement rather than confirmation.

Why both directions are plausible

Rapid weight loss of any cause is associated with telogen effluvium, a temporary shedding that follows a physiological stress by two to three months. That mechanism would predict hair loss on any effective weight-loss intervention rather than something specific to this drug class.

The opposite direction is also mechanistically ordinary: improving metabolic health can improve hair, and people losing weight often change their diet at the same time. With five studies pointing both ways, neither explanation has been isolated from the other.

What this means practically

If your hair sheds a few months into treatment, that is a recognized pattern after rapid weight loss and it is usually temporary — but it is also a reason to speak to a clinician rather than to read a forum, because iron, thyroid and protein intake all produce the same picture and all are checkable.

That is harder when nobody obvious is available to ask. Most of the sellers tracked here publish nothing about who reviews a case or how to reach them, which is the gap counted in what sellers will not tell you and listed in the questions they leave open. It is also worth knowing that rapid loss takes lean tissue as well as fat, which we cover in muscle loss on GLP-1 — the two effects share a cause even though only one of them is visible in a mirror.

Frequently asked

Do GLP-1 drugs cause hair loss?
The evidence does not settle it. A systematic review of five studies in 2,905 adults found conflicting results — some reporting hair loss as an adverse event, others reporting improvement and regrowth.
Why would it happen at all?
Rapid weight loss of any cause is associated with telogen effluvium, a temporary shedding that follows a physiological stress by a few months. That would apply to any effective weight-loss intervention.
What should I do if it happens?
Speak to a clinician rather than a forum. Iron, thyroid function and protein intake produce the same picture and are all checkable, and the pattern after rapid weight loss is usually temporary.

Sources

  1. [1] Alsuwailem OA, et al. (2025). Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review Cureus. PMID 41111833

More in Safety